🇺🇸 FDA
Pipeline program

NMRA-335140 80 mg

NMRA-335140-202

Phase 2 small_molecule completed

Quick answer

NMRA-335140 80 mg for Major Depressive Episode Associated With Bipolar II Disorder is a Phase 2 program (small_molecule) at Neumora Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Neumora Therapeutics
Indication
Major Depressive Episode Associated With Bipolar II Disorder
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials